Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
Authors
Keywords
-
Journal
BLOOD
Volume 135, Issue 15, Pages 1255-1269
Publisher
American Society of Hematology
Online
2020-04-10
DOI
10.1182/blood.2019002922
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1
- (2019) Christopher P Mill et al. BLOOD
- Enhancer dysfunction in leukemia
- (2018) Anand S. Bhagwat et al. BLOOD
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Mediator and RNA polymerase II clusters associate in transcription-dependent condensates
- (2018) Won-Ki Cho et al. SCIENCE
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
- (2018) Amanda Balboni Iniguez et al. CANCER CELL
- Phase Separation, Protein Disorder, and Enhancer Function
- (2018) Steven Hahn CELL
- Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains
- (2018) Ann Boija et al. CELL
- Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
- (2018) Dyana T. Saenz et al. LEUKEMIA
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
- (2017) Tyler E. Miller et al. NATURE
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
- (2016) D T Saenz et al. LEUKEMIA
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms
- (2016) Xiarong Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
- (2014) W Fiskus et al. LEUKEMIA
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- PVT1 dependence in cancer with MYC copy-number increase
- (2014) Yuen-Yi Tseng et al. NATURE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
- (2013) Wen Liu et al. CELL
- Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm
- (2013) Raajit Rampal et al. CURRENT OPINION IN HEMATOLOGY
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- Modification of Enhancer Chromatin: What, How, and Why?
- (2013) Eliezer Calo et al. MOLECULAR CELL
- Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
- (2013) Z Zou et al. ONCOGENE
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
- (2012) S.-J. Zhang et al. BLOOD
- An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
- (2012) Daniel Savic et al. PLoS One
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
- (2011) Madappa N. Kundranda et al. Current Hematologic Malignancy Reports
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Long-range enhancers on 8q24 regulate c-Myc
- (2010) J. Sotelo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- β-Catenin hits chromatin: regulation of Wnt target gene activation
- (2009) Christian Mosimann et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started